Phalanx Biotech Group was founded in 2003 as a result of collaboration between Taiwan's Industrial Technology Research Institute and several private companies and research institutes. It is a manufacturer of DNA microarrays and a provider of gene expression profiling services based in Hsinchu, Taiwan and in Belmont, California. The company sells its DNA microarrays under the registered trademark name OneArray.Phalanx Biotech Group is a member of the FDA-led Microarray Quality Control Project. Wikipedia.
Ting H.-W.,Taipei Hospital |
Ting H.-W.,Yuan Ze University |
Chen M.-S.,Taipei Veterans General Hospital |
Hsieh Y.-C.,Phalanx Biotech |
Chan C.-L.,Yuan Ze University
Journal of the Chinese Medical Association | Year: 2010
Background: How to effectively use the finite resources of an intensive care unit (ICU) for neurosurgical patients is a critical decision-making process. Mortality prediction models are effective tools for allocating facilities. This study intended to distinguish the prediction power of the Acute Physiology and Chronic Health Evaluation II (APACHE II), the Simplified Acute Physiology Score II (SAPS II), and the Glasgow Coma Scale (GCS) for neurosurgical patients. Methods: According to the definitions of the APACHE II, this study recorded both APACHE II and SAPS II scores of 154 neurosurgical patients in the ICU of a 600-bed general hospital. Linear regression models of GCS (GCS-mr) were constructed. The t test, receiver operating characteristic (ROC) curve and Wilcoxon signed rank test were used as the statistical evaluation methods. Results: There were 50 (32.5%) females and 104 (67.5%) males in this study. Among them, 108 patients survived and 46 patients died. The areas under the ROC curves (AUC) of SAPS II and APACHE II were 0.872 and 0.846, respectively. The AUC of GCS-mr was 0.866, and the R2 was 0.389. The evaluation powers of SAPS II, GCS-mr and APACHE II were the same (p > 0.05). Patients with GCS ≤ 5 or motor component of GCS (GCS-M) ≤ 3 had a higher probability of mortality than patients with GCS > 5 or GCS-M > 3 (p < 0.01). Conclusion: The predictive powers of SAPS II, APACHE II and GCS-mr were the same. The GCS-mr is more convenient for predicting mortality in neurosurgical patients. Both GCS ≤ 5 and GCS-M ≤ 3 are good indicators of mortality in these patients. © 2010 Elsevier.
News Article | November 24, 2016
MarketStudyReport.com adds “Global Microarray Market 2016-2020” new report to its research database. The report spread across 85 pages with table and figures in it. The Report analysts forecast the global microarray market to grow at a CAGR of 14.34% during the period 2016-2020. About Microarray A microarray is an advanced tool used in molecular biology. It allows end-users to conduct high-throughput and highly parallel analyses of more than thousand points of interest that include messenger ribonucleic acid (mRNA), genes, and proteins. Microarrays include a broad range of platforms in which high-density assays are conducted parallel on a solid support. The concept of the microarray is based on base-pairing hybridization principle (hybridization between nucleic acids). Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-microarray-market-2016-2020/ The report covers the present scenario and the growth prospects of the global microarray market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of microarray solutions such as instruments and consumables. The market is divided into the following segments based on geography: - Americas - APAC - EMEA The Report Global Microarray Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors - Agilent Technologies - Illumina - Thermo Fisher Scientific - Merck Other prominent vendors - Applied Microarrays - Arrayit - AXO Science - BioCat - BioGenex - Biometrix Technology - Cepheid - GE Healthcare - InDevR - LC Sciences - Perkin Elmer - Phalanx Biotech - Qiagen - Takara Bio - US Biomax. Market driver - Increased prevalence of chronic diseases - For a full, detailed list, view our report Market challenge - High cost of instruments - For a full, detailed list, view our report Market trend - Rising focus on drug discovery and development - For a full, detailed list, view our report Key questions answered in this report - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors- To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150
News Article | November 28, 2016
Notes: Production, means the output of Microarray Revenue, means the sales value of Microarray This report studies Microarray in Global Market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Agilent Technologies Illumina Thermo Fisher Scientific Merck Applied Microarrays Arrayit AXO Science BioCat BioGenex Biometrix Technology Cepheid GE Healthcare InDevR LC Sciences Perkin Elmer Phalanx Biotech Qiagen Takara Bio US Biomax. Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Microarray in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Southeast Asia India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Type I Type II Type III Split by application, this report focuses on consumption, market share and growth rate of Microarray in each application, can be divided into Application 1 Application 2 Application 3 Global Microarray Market Research Report 2016 1 Microarray Market Overview 1.1 Product Overview and Scope of Microarray 1.2 Microarray Segment by Type 1.2.1 Global Production Market Share of Microarray by Type in 2015 1.2.2 Type I 1.2.3 Type II 1.2.4 Type III 1.3 Microarray Segment by Application 1.3.1 Microarray Consumption Market Share by Application in 2015 1.3.2 Application 1 1.3.3 Application 2 1.3.4 Application 3 1.4 Microarray Market by Region 1.4.1 North America Status and Prospect (2011-2021) 1.4.2 Europe Status and Prospect (2011-2021) 1.4.3 China Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.4.5 Southeast Asia Status and Prospect (2011-2021) 1.4.6 India Status and Prospect (2011-2021) 1.5 Global Market Size (Value) of Microarray (2011-2021) 2 Global Microarray Market Competition by Manufacturers 2.1 Global Microarray Production and Share by Manufacturers (2015 and 2016) 2.2 Global Microarray Revenue and Share by Manufacturers (2015 and 2016) 2.3 Global Microarray Average Price by Manufacturers (2015 and 2016) 2.4 Manufacturers Microarray Manufacturing Base Distribution, Sales Area and Product Type 2.5 Microarray Market Competitive Situation and Trends 2.5.1 Microarray Market Concentration Rate 2.5.2 Microarray Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global Microarray Production, Revenue (Value) by Region (2011-2016) 3.1 Global Microarray Production by Region (2011-2016) 3.2 Global Microarray Production Market Share by Region (2011-2016) 3.3 Global Microarray Revenue (Value) and Market Share by Region (2011-2016) 3.4 Global Microarray Production, Revenue, Price and Gross Margin (2011-2016) 3.5 North America Microarray Production, Revenue, Price and Gross Margin (2011-2016) 3.6 Europe Microarray Production, Revenue, Price and Gross Margin (2011-2016) 3.7 China Microarray Production, Revenue, Price and Gross Margin (2011-2016) 3.8 Japan Microarray Production, Revenue, Price and Gross Margin (2011-2016) 3.9 Southeast Asia Microarray Production, Revenue, Price and Gross Margin (2011-2016) 3.10 India Microarray Production, Revenue, Price and Gross Margin (2011-2016) 4 Global Microarray Supply (Production), Consumption, Export, Import by Regions (2011-2016) 4.1 Global Microarray Consumption by Regions (2011-2016) 4.2 North America Microarray Production, Consumption, Export, Import by Regions (2011-2016) 4.3 Europe Microarray Production, Consumption, Export, Import by Regions (2011-2016) 4.4 China Microarray Production, Consumption, Export, Import by Regions (2011-2016) 4.5 Japan Microarray Production, Consumption, Export, Import by Regions (2011-2016) 4.6 Southeast Asia Microarray Production, Consumption, Export, Import by Regions (2011-2016) 4.7 India Microarray Production, Consumption, Export, Import by Regions (2011-2016) Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Calixto A.,Columbia University |
Ma C.,Columbia University |
Ma C.,University of Santiago de Chile |
Ma C.,Phalanx Biotech |
Chalfie M.,Columbia University
Nature Methods | Year: 2010
We describe a method for conditional regulation of gene expression based on the processing of an intron cassette. The RNA processing factor MEC-8 is necessary for the function of the Caenorhabditis elegans touch receptor neurons; mec-8 mutants are touch insensitive. We show here that this insensitivity involves the loss of MEC-8-dependent splicing of mec-2, which encodes a component of the mechanosensory transduction complex. MEC-8 is needed to remove the ninth intron in mec-2 pre-mRNA to form the longest of three mRNAs, mec-2a. Without MEC-8, splicing causes the termination of the transcript. Inclusion of mec-2 intron 9 is sufficient to convey mec-8-dependent regulation on other genes and, in mec-8(u218ts) mutants, resulted in their temperature-dependent expression. Because mec-8 is expressed ubiquitously in embryos and extensively in larvae, this system should produce temperature-sensitive expression for most genes. As an example, we report a strain that exhibits temperature-dependent RNA interference. © 2010 Nature America, Inc. All rights reserved.
Closek C.J.,Pennsylvania State University |
Closek C.J.,University of California at Merced |
Sunagawa S.,Structural and Computational Biology Unit |
Desalvo M.K.,Phalanx Biotech |
And 9 more authors.
ISME Journal | Year: 2014
Coral diseases impact reefs globally. Although we continue to describe diseases, little is known about the etiology or progression of even the most common cases. To examine a spectrum of coral health and determine factors of disease progression we examined Orbicella faveolata exhibiting signs of Yellow Band Disease (YBD), a widespread condition in the Caribbean. We used a novel combined approach to assess three members of the coral holobiont: the coral-host, associated Symbiodinium algae, and bacteria. We profiled three conditions: (1) healthy-appearing colonies (HH), (2) healthy-appearing tissue on diseased colonies (HD), and (3) diseased lesion (DD). Restriction fragment length polymorphism analysis revealed health state-specific diversity in Symbiodinium clade associations. 16S ribosomal RNA gene microarrays (PhyloChips) and O. faveolata complimentary DNA microarrays revealed the bacterial community structure and host transcriptional response, respectively. A distinct bacterial community structure marked each health state. Diseased samples were associated with two to three times more bacterial diversity. HD samples had the highest bacterial richness, which included components associated with HH and DD, as well as additional unique families. The host transcriptome under YBD revealed a reduced cellular expression of defense- and metabolism-related processes, while the neighboring HD condition exhibited an intermediate expression profile. Although HD tissue appeared visibly healthy, the microbial communities and gene expression profiles were distinct. HD should be regarded as an additional (intermediate) state of disease, which is important for understanding the progression of YBD. © 2014 International Society for Microbial Ecology. All rights reserved.
Xu H.,University of Connecticut Health Center |
Sobue T.,University of Connecticut Health Center |
Thompson A.,University of Connecticut Health Center |
Xie Z.,University of Connecticut Health Center |
And 5 more authors.
Cellular Microbiology | Year: 2014
Summary: Mitis-group streptococci are ubiquitous oral commensals that can promote polybacterial biofilm virulence. Using a novel murine oral mucosal co-infection model we sought to determine for the first time whether these organisms promote the virulence of C.albicans mucosal biofilms in oropharyngeal infection and explored mechanisms of pathogenic synergy. We found that Streptococcus oralis colonization of the oral and gastrointestinal tract was augmented in the presence of C.albicans. S.oralis and C.albicans co-infection significantly augmented the frequency and size of oral thrush lesions. Importantly, S.oralis promoted deep organ dissemination of C.albicans. Whole mouse genome tongue microarray analysis showed that when compared with animals infected with one organism, the doubly infected animals had genes in the major categories of neutrophilic response/chemotaxis/inflammation significantly upregulated, indicative of an exaggerated inflammatory response. This response was dependent on TLR2 signalling since oral lesions, transcription of pro-inflammatory genes and neutrophil infiltration, were attenuated in TLR2-/- animals. Furthermore, S.oralis activated neutrophils in a TLR2-dependent manner in vitro. In summary, this study identifies a previously unrecognized pathogenic synergy between oral commensal bacteriaand C.albicans. This is the first report of the ability of mucosal commensal bacteria to modify the virulence of an opportunistic fungal pathogen. © 2013 John Wiley & Sons Ltd.
Phalanx Biotech | Date: 2010-11-02
Biological protein, DNA, and cell microarrays for scientific and medical research; reagents for scientific or medical research use. Providing chemical screening analysis and medical research using biological microarrays.
Phalanx Biotech | Date: 2010-11-16
Biological protein, DNA, and cell microarrays; medical reagents for scientific research use. Medical diagnostic reagents for testing use. Laboratory device, namely, biochips for the identification and detection of biological material from a sample; biochemical analyzers for use with biological microarrays, namely, diagnostic detection unit comprised of an assay, reader, analysis software and database management software for use in biopharmaceutical research. Providing temporary use of non-downloadable computer software for chemical screening analysis and medical research using biological microarrays.
News Article | July 9, 2015
According to a new market research report "Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR), Consumables (Genechips, Reagents for DNA Extraction & Purification, Sequencing)], Services (Sequencing & Microarray Services, and Software) - Global Forecast to 2018", published by MarketsandMarkets, the global Genomics Market earned revenues of $11.11 Billion in 2013 and estimates this market to reach over $19.0 Billion by 2018. Browse 49 market data tables and 52 figures spread through 248 pages and in-depth TOC on "Genomics Market" http://www.marketsandmarkets.com/Market-Reports/genomics-market-613.html Early buyers will receive 10% customization on this report. The global Genomics Market was dominated by Tier I players such as Roche Diagnostics, Life Technologies, QIAGEN, Illumina, and Bio-Rad. Roche Diagnostics was the market leader in the global genomics market in 2013. This may be attributed to its strategic integration with NimbleGen's MS 200 microarray scanner, as well as its co-promotional agreement with SoftGenetics in 2012. Significant Tier II players include BGI, PerkinElmer, and Hologic Gen-Probe, and Tier III companies included Oxford Gene Technology, Knome, and Phalanx Biotech. Notable tier IV players in this market were LGC Genomics and DNA STAR. The Global Genomics market was found to be increasingly consolidated, owing to various restructuring activities in the past five years. Tier I and Tier II companies were the key acquirers, while Tier III companies were found to be the targets of M&A activities. Besides mergers and acquisitions, alliances were also a prominent strategy amongst leading players. Technology licensing was the most prevalent motive of such alliances. The acquisition of Life Technologies by Thermo Fischer in 2014 is expected to significantly change the competitive landscape of the global genomics market, as two key players in this market merge to consolidate Thermo Fischer's market shares in coming years. The Instrument and Consumables product segments were dominated by companies with a global presence, while the Services market was dominated by small to medium-scale service providers with a regional presence. Based on technology, the PCR technology segment accounted for the largest revenue share of the global genomics technology market in 2013. However, the DNA sequencing technology segment is expected to grow significantly during the forecast period. Market adoption of silica-based technology and magnetic bead technology was highest in the nucleic acid extraction and purification technology segment. The fast spin technology was found to be the most promising upcoming technology, as it offers improved clinical efficiency, and reduced time and cost. Other technology sub-segments expected to witness high rates of adoption include optical microarrays, micro fluidic systems, sequencing by synthesis (SBS), and single-molecule real-time (SMRT). North America accounted for the highest share of revenues from the global Genomics Market, owing to the region's focus on genomics research to improve human health. The APAC region is expected to witness the highest CAGR during the forecast period, owing to the increasing awareness of genomics applications in this region. Notable emerging regional markets for genomics include India, China, South Korea, Mexico, Brazil, Russia, and Turkey. MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Contact: Mr. Rohan North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas, TX 75252 Tel: +1-888-600-6441 Email: firstname.lastname@example.org Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets